- Home
- EDF vs MIST Comparison
EDF vs MIST Comparison
Compare EDF & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- MIST
- Stock Information
- Founded
- EDF 2010
- MIST 2003
- Country
- EDF United States
- MIST Canada
- Employees
- EDF N/A
- MIST N/A
- Industry
- EDF Investment Managers
- MIST Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- MIST Health Care
- Exchange
- EDF Nasdaq
- MIST Nasdaq
- Market Cap
- EDF 156.6M
- MIST 132.5M
- IPO Year
- EDF N/A
- MIST N/A
- Fundamental
- Price
- EDF $5.09
- MIST $1.70
- Analyst Decision
- EDF
- MIST Strong Buy
- Analyst Count
- EDF 0
- MIST 2
- Target Price
- EDF N/A
- MIST $7.50
- AVG Volume (30 Days)
- EDF 160.6K
- MIST 968.0K
- Earning Date
- EDF 01-01-0001
- MIST 08-12-2025
- Dividend Yield
- EDF 13.14%
- MIST N/A
- EPS Growth
- EDF N/A
- MIST N/A
- EPS
- EDF N/A
- MIST N/A
- Revenue
- EDF N/A
- MIST N/A
- Revenue This Year
- EDF N/A
- MIST N/A
- Revenue Next Year
- EDF N/A
- MIST N/A
- P/E Ratio
- EDF N/A
- MIST N/A
- Revenue Growth
- EDF N/A
- MIST N/A
- 52 Week Low
- EDF $3.51
- MIST $0.63
- 52 Week High
- EDF $5.50
- MIST $2.75
- Technical
- Relative Strength Index (RSI)
- EDF 51.75
- MIST 54.89
- Support Level
- EDF $5.05
- MIST $1.61
- Resistance Level
- EDF $5.18
- MIST $1.56
- Average True Range (ATR)
- EDF 0.04
- MIST 0.08
- MACD
- EDF -0.00
- MIST 0.03
- Stochastic Oscillator
- EDF 47.78
- MIST 88.24
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).